Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
 

Search in our Online Store

R&D Pipeline News Vol. 2, Issue 24: Johnson & Johnson: full development pipeline Print E-mail
26 Jun 2006
Read the highlights of the most recent edition of our weekly R&D information product R&D Pipeline News. The Special Product or Technology Pipelines of R&D Pipeline News are available via subscription of R&D Pipeline News or as a single Project Pipeline List .



Special Company Pipeline:

Featured Pipelines:

Vol. 2 Issue nº 24
June 26, 2006





Special Company Pipeline:

Johnson & Johnson: full development pipeline

  • 18 new molecular entities (NMEs) in full development;
  • 74 NMEs in early clinical development;
  • 160 NMEs in late drug discovery;
  • Only two antibodies among 18 late development projects;
  • Strong focus on neurology & psychiatry and infectious diseases;
  • Half of late pipeline directly originating from external sources;

  • More Details inside R&D Pipeline News

    Get you annual subscription and receive this issue for free!

    Top

Featured Pipelines

Pipeline Update: Thrombolytics

  • ImaRx acquired all thrombolytic projects from Abbott;
  • Innovative combinations of thrombolytic with ultrasound;
  • New uses of thrombolytics for cancer and visual disorders;
  • Strong interest in thrombolytics which directly lyse fibrin;
  • Plasmin and microplasmin as novel thrombolytics
  • No biogeneric thrombolytics in Europe , but plenty in emerging markets;
  • Biogenerics include rec streptokinase, t-PA, tenecteplase and reteplase.

More Details inside R&D Pipeline News
Get you annual subscription and receive this issue for free!

    Top

Product Pipeline: female sexual arousal disorder (FSAD)

  • Most development projects use testosterone;
  • Significant improvements of FSAD achieved with testosterone patch in phase III;
  • New class of centrally acting sexual stimulants
  • Pan-melanocortin receptor agonist in advanced phase II for FSAD;
  • Also evaluated in male erectile dysfunction
  • Topical prostaglandins in advanced clinical development

More Details inside R&D Pipeline News
Get you annual subscription and receive this issue for free!

    Top

R&D Pipeline News
Get your Subscription Now

R&D Pipeline News is a premier information source about research and development (R&D) projects in the pipeline of the biopharmaceutical industry and is directed to all stakeholders in R&D . R&D Pipeline News covers all relevant treatment modalities, including. drugs, medical devices, biomaterials, combination products, cell therapy and drug delivery products.
Read more about R&D Pipeline NewsOrder Now





Digg!Reddit!Del.icio.us!Google!Live!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Spurl!Wists!Simpy!Newsvine!Blinklist!Furl!Fark!Blogmarks!Yahoo!Smarking!Netvouz!Shadows!RawSugar!Ma.gnolia!PlugIM!Squidoo!BlogMemes!FeedMeLinks!BlinkBits!Tailrank!linkaGoGo!Free social bookmarking plugins and extensions for Joomla! websites! title=
 

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics